[Expert consensus on the use of pegylated recombinant human granulocyte colony-stimulating factor in the treatment of hematologic malignancies (2026 edition)].

Abstract

Neutropenia is one of the most common hematologic toxicities during the treatment of hematologic malignancies. It can lead to delays in subsequent treatments, dose reduction of chemotherapeutic agents, or even treatment discontinuation. Furthermore, neutropenia increases the risk of febrile neutropenia and severe infections, which adversely affect patient prognosis. Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is effective in preventing and treating neutropenia, and is widely used in the treatment of hematologic malignancies and hematopoietic stem cell transplantation (HSCT). To further promote the standardized application of PEG-rhG-CSF in hematological malignancies, the Hematology Oncology Committee of China Anti-Cancer Association organized domestic experts in the related fields, based on current evidence-based medical data and clinical practice, to focus on the clinical application of PEG-rhG-CSF in hematologic malignancies, hematopoietic stem cell mobilization and hematopoietic function reconstitution after HSCT. Eight recommendation opinions were finally proposed to guide the standardized use of drugs in clinical practice.

中性粒细胞减少症是血液系统恶性肿瘤治疗过程中最常见的血液学毒性之一，可导致后续治疗延迟、化疗药物剂量减少甚至治疗终止，增加中性粒细胞减少性发热及严重感染的风险，影响患者预后。聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）可有效预防和治疗中性粒细胞减少症，广泛应用于血液肿瘤治疗及造血干细胞移植（HSCT）领域。为进一步规范血液系统肿瘤中PEG-rhG-CSF的应用，中国抗癌协会血液肿瘤专业委员会组织国内相关领域专家，基于现有的循证医学证据并结合临床实践，围绕PEG-rhG-CSF在血液系统肿瘤、造血干细胞动员与HSCT后造血功能重建等方面的临床应用，最终形成8条推荐意见，以指导临床规范用药。.